Misoprostol is an effective noninvasive method to complete abortion in missed abortions, a new meta-analysis reveals. Moreover, sublingual doses of 600 µg or vaginal doses of 800 µg may potentially be good first doses.
Use of varenicline and bupropion, medication to help quit smoking, is unlikely to be associated with increased risks of cardiovascular (CV) and neuropsychiatric adverse events compared with nicotine replacement therapy (NRT) in smokers with chronic obstructive pulmonary disease (COPD), in contrast to previous belief.
Daily intake of lactoferrin with vitamin E and zinc appears to safely and effectively reduce acne lesions in individuals with mild-to-moderate acne vulgaris compared with placebo, according to a study.
Adding doxycycline to prednisolone did not appear to improve time to exacerbation in patients with mild-to-severe chronic obstructive pulmonary disease (COPD) treated in an outpatient setting, according to a study from the Netherlands.
A new guideline on when to deprescribe proton pump inhibitors (PPIs) in the setting of gastroesophageal reflux disease (GERD) and other upper gastrointestinal (GI) symptoms will guide clinicians’ treatment decisions amid increasing concerns over PPI overuse.
The US FDA recently granted accelerated approval to pembrolizumab for the treatment of adult and paediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumours.
It appears that prescribing immediate antibiotics does not lessen major adverse outcomes of subsequent hospital admission or death for young people and adults with uncomplicated lower respiratory tract infection, a recent study has shown.
Patients with stable schizophrenia may benefit from long-term antipsychotic treatment, with a recent meta-analysis finding that continuation of antipsychotics over a 1-year period significantly reduces symptom exacerbation in this population in contrast to a trajectory of continuous symptom exacerbation in patients on placebo.
New drug applications approved by US FDA as of 1 - 15 February 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Valsartan/sacubitril (formerly LCZ696), recently approved by the US Food and Drug Administration for treating heart failure, may also be beneficial for reducing blood pressure (brachial and central aortic pressure) as well as arterial stiffness compared with angiotensin receptor blocker olmesartan.
New drug applications approved by US FDA as of 16 - 31 Dec 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.